Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Labor/HHS approps

This article was originally published in The Tan Sheet

Executive Summary

Senate bill passes 89-10 Nov. 6 with measure that would provide NIH Office of Dietary Supplements with up to $20 mil. to "continue and expand" ephedra safety/efficacy research, botanical research centers. HR 3061 also allocates $110 mil. to NCCAM for FY 2002; House version, which passed Oct. 11, offers $99.3 mil. for NIH center. Senate bill includes amendment by Sens. Orrin Hatch (R-Utah), Tom Harkin (D-Iowa) providing $500,000 to cover labeling enforcement under DSHEA, language urging publication of supplement GMPs within 15 days of bill enactment (1"The Tan Sheet" Nov. 5, In Brief). Conferees, including Harkin, likely will meet week of Nov. 12 to reconcile differences...

Senate bill passes 89-10 Nov. 6 with measure that would provide NIH Office of Dietary Supplements with up to $20 mil. to "continue and expand" ephedra safety/efficacy research, botanical research centers. HR 3061 also allocates $110 mil. to NCCAM for FY 2002; House version, which passed Oct. 11, offers $99.3 mil. for NIH center. Senate bill includes amendment by Sens. Orrin Hatch (R-Utah), Tom Harkin (D-Iowa) providing $500,000 to cover labeling enforcement under DSHEA, language urging publication of supplement GMPs within 15 days of bill enactment (1 'The Tan Sheet' Nov. 5, In Brief). Conferees, including Harkin, likely will meet week of Nov. 12 to reconcile differences....

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS093262

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel